CYTOKINETICS INC (CYTK) FY2025 10-K Annual Report
CYTOKINETICS INC (CYTK) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
CYTOKINETICS INC FY2025 10-K Analysis
Business Overview
- • Core business model: biopharmaceutical development and commercialization focused on muscle biology therapeutics for cardiovascular diseases
- • New product launch: MYQORZO approved by FDA in Dec 2025 for symptomatic oHCM, first commercial sales commenced Q1 2026
- • Strategic shift: transition from R&D focus to commercial readiness and sales activities for MYQORZO in US and Europe
- • Financial metric: cash, cash equivalents, and marketable securities $1.22B (2025), borrowings increased to $1.33B from $805M in 2024
- • Noteworthy fact: entered multiple substantial royalty monetization and debt financings including $750M 2031 Notes issuance and renegotiated out-licenses in Greater China and Japan
Management Discussion & Analysis
- • Revenue $88.1M in 2025, up $69.6M from $18.5M in 2024, driven by license and milestone revenues from Bayer and Sanofi
- • Operating expenses rose sharply: R&D $416.0M (+23% YoY), G&A $284.3M (+32% YoY), reflecting clinical advancement and commercial readiness
- • Best segment license/milestone revenues $79.4M in 2025 vs $15.0M in 2024; collaboration revenue $8.7M in 2025 vs $3.5M in 2024
- • Cash use in 2025 driven by $100M loan draw, $121.2M debt conversion expense, increased interest expense $45.6M (up $7.9M YoY); expect higher SG&A in 2026 due to commercialization
- • Management expects flat to declining R&D in 2026; key risks: regulatory approvals, market acceptance of MYQORZO, limitations from FDA partial clinical hold on CK-089 trial
Risk Factors
- • Cybersecurity risk oversight led by Audit Committee with tech, risk, finance expertise and regular briefings from CISO, CEO, CFO
- • Dependence on Chief Information Security Officer Eric Brown with 10+ years cybersecurity experience for managing critical security operations
- • Cybersecurity incident response plan includes immediate impact mitigation and long-term remediation strategies
- • Ongoing Board and Audit Committee dialogue on emerging cybersecurity threats ensures proactive risk governance
- • No specific regulatory, geopolitical, operational supply chain, competitive, or financial risks detailed in this section
CYTOKINETICS INC FY2025 Key Financial MetricsXBRL
Revenue
$88M
▲ +376.6% YoY
Net Income
-$785M
▼ -33.2% YoY
Operating Margin
-695.4%
▲ +220728bp YoY
Net Margin
-891.6%
▲ +229951bp YoY
ROE
119.0%
▼ -31649bp YoY
Total Assets
$1.4B
▲ +1.6% YoY
EPS (Diluted)
$-6.54
▼ -24.3% YoY
Operating Cash Flow
-$510M
▼ -28.8% YoY
Source: XBRL data from CYTOKINETICS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CYTOKINETICS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.